AM05879HR-N Rituximab antibody

See related secondary antibodies

Search for all "Rituximab"

0.1 mg / €850.00
Please visit the country specific website of Acris Antibodies or contact your local Distributor to buy this product.

Quick Overview

Rat anti Rituximab MB2 A4

Product Description for Rituximab

Rat anti Rituximab MB2 A4.
Presentation: HRP
Product is tested for Enzyme Immunoassay.

Properties for Rituximab

Product Category Primary Antibodies
Quantity 0.1 mg
Synonyms MabThera, Rituxan
Presentation HRP
Applications E
Clonality Monoclonal
Clone MB2 A4
Host Rat
Isotype IgG2a
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer Acris Antibodies GmbH
Material safety datasheet MSDS for Monoclonal Antibodies (de)

Datasheet Extract

F(ab)2 fragment of Rituximab
Isotype control SM15P, SM15PX
Application ELISA: 1/20000-1/20000.
Background Rituximab is a therapeutic reagent directed against the human CD20 cell surface antigen.
Concentration 1.0 mg/ml
General Readings
  1. Bayne, M. et al. (2003) Phase I/II study of fractionated radioimmunotherapy in relapsed low grade non Hodgkin lymphoma. Br. J. Cancer. 88 : S38.
  2. Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ. Apparent modulation of CD20 by rituximab: an alternative explanation. Blood. 2004 May 15;103(10):3989-90; author reply 3990-1. PubMed PMID: 15121717.
  3. Beum PV, Kennedy AD, Li Y, Pawluczkowycz AW, Williams ME, Taylor RP. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. J Immunol Methods. 2004 Nov;294(1-2):37-42. PubMed PMID: 15604014.
  4. Hampson G, Ward TH, Cummings J, Bayne M, Tutt AL, Cragg MS, et al. Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. J Immunol Methods. 2010 Aug 31;360(1-2):30-8. doi: 10.1016/j.jim.2010.05.009. Epub 2010 Jun 11. PubMed PMID: 20547164.
  5. Blasco H, Lalmanach G, Godat E, Maurel MC, Canepa S, Belghazi M, et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods. 2007 Aug 31;325(1-2):127-39. Epub 2007 Jul 17. PubMed PMID: 17651747.
  6. Daydé D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009 Apr 16;113(16):3765-72. doi: 10.1182/blood-2008-08-175125. Epub 2008 Nov 24. PubMed PMID: 19029438.
  7. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41. doi: 10.1073/pnas.1102855108. Epub 2011 Aug 25. PubMed PMID: 21873242. (Free PMC Article available, 6 images available)
  8. Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol. 2009 Sep;132(3):334-41. doi: 10.1016/j.clim.2009.05.007. Epub 2009 Jun 7. PubMed PMID: 19502112.
  9. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010 Jun;8(6):1201-8. doi: 10.1111/j.1538-7836.2010.03818.x. Epub 2010 Feb 19. PubMed PMID: 20175870.
  10. Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res. 2012 Feb;29(2):490-9. doi: 10.1007/s11095-011-0578-3. Epub 2011 Sep 2. PubMed PMID: 21887597.
  11. Kagan L, Mager DE. Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos. 2013 Jan;41(1):248-55. doi: 10.1124/dmd.112.048496. Epub 2012 Nov 5. PubMed PMID: 23129212.
  12. Cragg MS, Bayne MB, Tutt AL, French RR, Beers S, Glennie MJ, et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood. 2004 Oct 15;104(8):2540-2. Epub 2004 Jun 22. PubMed PMID: 15213098.
Storage Store undiluted at 2-8°C.
Shelf life: one year from despatch.
Affinity chromatography on Protein G
Buffer System:
0.01% Thiomersal
HRP stabilizer (containg no Azide, no Mercury, no BSA or other Bovine material, but weak concentrations of Rabbit antibodies).
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Liquid purified IgG fraction from Tissue Culture Supernatant
This antibody specifically recognises the idiotypic determinants expressed by the Rituximab humanised monoclonal antibody. 
This antibody does not recognise other CD20 antibodies.
It has been used to detect Rituximab bound to the surface of the Raji B cell line, however detection of Rituximab bound 'in vivo' to B-CLL cells has not been demonstrated. It is possible that complement deposition on Rituximab opsonised cells inhibits binding of the anti-Rituximab antibody to cell bound Rituximab (3).
Clone MB2A4 has been used in ELISA assays to monitor the levels of rituximab in patient serum following therapy (4,5).

Accessory Products

  • LinkedIn